Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
VolitionRX ( (VNRX) ) has provided an update.
At the Annual Meeting on June 18, 2025, VolitionRX‘s stockholders voted on four proposals. The stockholders elected eight members to the Board of Directors, ratified the selection of Sadler, Gibb & Associates, LLC as the independent registered public accounting firm, approved the compensation of the company’s named executive officers, and approved an amendment to the Restated Certificate.
The most recent analyst rating on (VNRX) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Neutral.
The overall stock score of 51 reflects the company’s challenging financial position, tempered by positive developments from the earnings call. The most significant factor is the financial performance, which is notably weak. However, promising strategic initiatives and revenue growth provide potential upside. Technical analysis indicates positive momentum but warns of potential overbought conditions.
To see Spark’s full report on VNRX stock, click here.
More about VolitionRX
Average Trading Volume: 265,925
Technical Sentiment Signal: Sell
Current Market Cap: $69.15M
Learn more about VNRX stock on TipRanks’ Stock Analysis page.